. 2020 Sep;15(4).
doi: 10.1159/000509362.

Endocrine Therapy in Early Breast Cancer

Katja Krauss 1 Elmar Stickeler 1 
  • PMID: 32982643
  •     86 References


Background: Endocrine therapy with a standard duration of 5 years is well known as an effective treatment for endocrine-sensitive breast cancer.

Summary: In the adjuvant setting this treatment reduces the 15-year mortality rates by about 30 and 40% with tamoxifen and aromatase inhibitor, respectively. The well-known long-term recurrence risk of luminal cancers led to multiple trials examining the benefit of extended endocrine treatment for up to 15 years. Additional benefit with extended therapy was seen for patients with high recurrence risk. Also, additional ovarian suppression for premenopausal women exhibited a significant benefit for patients at higher risk.

Key Messages: The data of the last years will be summarized and discussed, also considering the side effects of the different treatment options.

Keywords: Aromatase inhibitor; Chemotherapy-induced ovarian failure; Extended endocrine therapy; Late recurrence; Neoadjuvant endocrine therapy; Ovarian function suppression; Tamoxifen.

Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Ivana Sestak, Richard Buus, +9 authors, Mitch Dowsett.
JAMA Oncol, 2018 Feb 17; 4(4). PMID: 29450494    Free PMC article.
Highly Cited.
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.
Giampaolo Bianchini, Lajos Pusztai, +16 authors, Luca Gianni.
Breast Cancer Res, 2013 Sep 26; 15(5). PMID: 24060333    Free PMC article.
Early discontinuation of tamoxifen: a lesson for oncologists.
Thomas I Barron, Róisín Connolly, +2 authors, M John Kennedy.
Cancer, 2007 Jan 24; 109(5). PMID: 17243168
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.
Thomas Ruhstaller, Anita Giobbie-Hurder, +27 authors, members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group.
J Clin Oncol, 2018 Nov 27; 37(2). PMID: 30475668    Free PMC article.
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
Erik J Blok, Judith R Kroep, +10 authors, IDEAL Study Group.
J Natl Cancer Inst, 2017 Sep 20; 110(1). PMID: 28922787
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Matthew J Ellis, Vera J Suman, +28 authors, Kelly Hunt.
J Clin Oncol, 2017 Jan 04; 35(10). PMID: 28045625    Free PMC article.
Highly Cited.
Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27.
K Strasser-Weippl, G Sudan, +6 authors, P E Goss.
Eur J Cancer, 2017 Dec 24; 90. PMID: 29274617
Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
Tara Sanft, Bilge Aktas, +11 authors, Lajos Pusztai.
Breast Cancer Res Treat, 2015 Nov 19; 154(3). PMID: 26578401    Free PMC article.
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
Poornima Saha, Meredith M Regan, +25 authors, International Breast Cancer Study Group.
J Clin Oncol, 2017 Jun 28; 35(27). PMID: 28654365    Free PMC article.
The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
Jeanine Marie Nardin, Werner Schroth, +11 authors, José Claudio Casali-da-Rocha.
Clin Transl Sci, 2019 Oct 02; 13(2). PMID: 31573754    Free PMC article.
Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
Eitan Amir, Bostjan Seruga, +2 authors, Alberto Ocaña.
J Natl Cancer Inst, 2011 Jul 12; 103(17). PMID: 21743022
Highly Cited. Systematic Review.
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
Mitch Dowsett, Ivana Sestak, +5 authors, Jack Cuzick.
J Clin Oncol, 2018 Apr 21; 36(19). PMID: 29676944    Free PMC article.
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Vivianne C G Tjan-Heijnen, Irene E G van Hellemond, +14 authors, Dutch Breast Cancer Research Group (BOOG) for the DATA Investigators.
Lancet Oncol, 2017 Oct 17; 18(11). PMID: 29031778
Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer.
Takayuki Ueno, Norikazu Masuda, +12 authors, Masakazu Toi.
Int J Clin Oncol, 2013 Oct 09; 19(4). PMID: 24101215
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.
Meredith M Regan, Prudence A Francis, +12 authors, Richard D Gelber.
J Clin Oncol, 2016 Apr 06; 34(19). PMID: 27044936    Free PMC article.
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
Eleftherios P Mamounas, Jong-Hyeon Jeong, +17 authors, Norman Wolmark.
J Clin Oncol, 2008 Mar 12; 26(12). PMID: 18332472
Adjuvant ovarian suppression in premenopausal breast cancer.
Prudence A Francis, Meredith M Regan, +28 authors, International Breast Cancer Study Group.
N Engl J Med, 2014 Dec 17; 372(5). PMID: 25495490    Free PMC article.
Highly Cited.
Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial.
Hyun-Ah Kim, Jong Won Lee, +27 authors, Korean Breast Cancer Study Group.
J Clin Oncol, 2019 Sep 14; 38(5). PMID: 31518174
Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure.
Irene E G van Hellemond, Ingeborg J H Vriens, +16 authors, Dutch Breast Cancer Research Group (BOOG).
J Natl Cancer Inst, 2018 Mar 17; 109(12). PMID: 29546343
Facilitating breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings.
Eleftherios P Mamounas.
Ann Surg Oncol, 2008 Jan 16; 15(3). PMID: 18196346
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
Kimberly H Allison, M Elizabeth H Hammond, +17 authors, Antonio C Wolff.
J Clin Oncol, 2020 Jan 14; 38(12). PMID: 31928404
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
Young Chai Lim, Zeruesenay Desta, David A Flockhart, Todd C Skaar.
Cancer Chemother Pharmacol, 2005 Feb 03; 55(5). PMID: 15685451
Ovarian Suppression in Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Kathy Pan, Linda Diana Bosserman, Rowan T Chlebowski.
J Clin Oncol, 2019 Feb 12; 37(11). PMID: 30742565
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Matthew J Ellis, Yu Tao, +9 authors, Mitch Dowsett.
J Natl Cancer Inst, 2008 Sep 25; 100(19). PMID: 18812550    Free PMC article.
Highly Cited.
The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen.
Anabel B Sanchez-Spitman, Dirk-Jan Ar Moes, +3 authors, Henk-Jan Guchelaar.
Pharmacogenomics, 2017 Jul 27; 18(12). PMID: 28745555
Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence.
Yi Zhang, Catherine A Schnabel, +7 authors, Mark G Erlander.
Clin Cancer Res, 2013 Jun 13; 19(15). PMID: 23757354
Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
Lisa Rydén, Marianne Heibert Arnlind, +2 authors, Johan Ahlgren.
Breast, 2016 Mar 29; 26. PMID: 27017249
Systematic Review.
Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.
Huan Jin, Dongsheng Tu, +2 authors, Paul E Goss.
J Clin Oncol, 2011 Nov 02; 30(7). PMID: 22042967    Free PMC article.
Which threshold for ER positivity? a retrospective study based on 9639 patients.
M Yi, L Huo, +11 authors, K K Hunt.
Ann Oncol, 2014 Feb 25; 25(5). PMID: 24562447    Free PMC article.
Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review.
Anthony Matthews, Susannah Stanway, +5 authors, Krishnan Bhaskaran.
BMJ, 2018 Oct 10; 363. PMID: 30297439    Free PMC article.
Systematic Review.
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
Eleftherios P Mamounas, Hanna Bandos, +17 authors, Norman Wolmark.
Lancet Oncol, 2018 Dec 05; 20(1). PMID: 30509771    Free PMC article.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Olivia Pagani, Meredith M Regan, +32 authors, International Breast Cancer Study Group.
N Engl J Med, 2014 Jun 03; 371(2). PMID: 24881463    Free PMC article.
Highly Cited.
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.
E Alba, L Calvo, +10 authors, GEICAM.
Ann Oncol, 2012 Jun 08; 23(12). PMID: 22674146
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Paul E Goss, James N Ingle, +18 authors, Lois E Shepherd.
J Clin Oncol, 2013 Jan 30; 31(11). PMID: 23358971    Free PMC article.
Highly Cited.
Extended duration of adjuvant aromatase inhibitor in breast cancer: a meta-analysis of randomized controlled trials.
Zackariah Clement, James Kollias, +2 authors, Melissa Bochner.
Gland Surg, 2018 Dec 07; 7(5). PMID: 30505766    Free PMC article.
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
P E Goss, J N Ingle, +11 authors, D Tu.
Ann Oncol, 2012 Oct 03; 24(2). PMID: 23028039    Free PMC article.
Endocrine Therapy for Early Breast Cancer: Updated Review.
Alexander Tremont, Jonathan Lu, John T Cole.
Ochsner J, 2017 Dec 13; 17(4). PMID: 29230126    Free PMC article.
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
Harold J Burstein, Christina Lacchetti, +9 authors, Jennifer J Griggs.
J Clin Oncol, 2018 Nov 20; 37(5). PMID: 30452337
Highly Cited. Systematic Review.
Breast cancer statistics, 2019.
Carol E DeSantis, Jiemin Ma, +5 authors, Rebecca L Siegel.
CA Cancer J Clin, 2019 Oct 03; 69(6). PMID: 31577379
Highly Cited.
Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial.
Patrick Neven, Lynn Jongen, +22 authors, Henk-Jan Guchelaar.
Clin Cancer Res, 2018 Feb 21; 24(10). PMID: 29459457
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Aleix Prat, Cristina Saura, +27 authors, Joaquín Gavilá.
Lancet Oncol, 2019 Dec 16; 21(1). PMID: 31838010
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
M Gnant, B Mlineritsch, +23 authors, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.
Ann Oncol, 2014 Nov 19; 26(2). PMID: 25403582
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
Mitch Dowsett, Ian E Smith, +8 authors, IMPACT Trialists Group.
J Natl Cancer Inst, 2007 Jan 18; 99(2). PMID: 17228000
Highly Cited.
Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells.
Jeanette A Richards, Trevor A Petrel, Robert W Brueggemeier.
J Steroid Biochem Mol Biol, 2002 Mar 19; 80(2). PMID: 11897504
Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
J M S Bartlett, D C Sgroi, +8 authors, D W Rea.
Ann Oncol, 2019 Sep 11; 30(11). PMID: 31504126    Free PMC article.
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
Hongchao Pan, Richard Gray, +9 authors, EBCTCG.
N Engl J Med, 2017 Nov 09; 377(19). PMID: 29117498    Free PMC article.
Highly Cited.
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Meredith M Regan, Patrick Neven, +14 authors, International Breast Cancer Study Group (IBCSG).
Lancet Oncol, 2011 Oct 25; 12(12). PMID: 22018631    Free PMC article.
Highly Cited.
Aromatase and breast cancer.
A Brodie, G Sabnis, D Jelovac.
J Steroid Biochem Mol Biol, 2006 Nov 23; 102(1-5). PMID: 17113978    Free PMC article.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Lyndsay N Harris, Nofisat Ismaila, +11 authors, American Society of Clinical Oncology.
J Clin Oncol, 2016 Feb 10; 34(10). PMID: 26858339    Free PMC article.
Highly Cited. Review.
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Dennis C Sgroi, Ivana Sestak, +9 authors, Mitch Dowsett.
Lancet Oncol, 2013 Sep 17; 14(11). PMID: 24035531    Free PMC article.
Highly Cited.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Christina Davies, Hongchao Pan, +36 authors, Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.
Lancet, 2012 Dec 12; 381(9869). PMID: 23219286    Free PMC article.
Highly Cited.
Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer.
Rachel C Jankowitz, Kristine Cooper, +5 authors, Adam Brufsky.
Breast Cancer Res, 2011 Oct 18; 13(5). PMID: 21999244    Free PMC article.
Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
Vincent O Dezentjé, Nico J C van Blijderveen, +6 authors, Henk-Jan Guchelaar.
J Clin Oncol, 2010 Apr 14; 28(14). PMID: 20385997
Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.
Rodrigo R Munhoz, Allan A L Pereira, +4 authors, Ricardo J Marques.
JAMA Oncol, 2015 Oct 02; 2(1). PMID: 26426573    Free PMC article.
Systematic Review.
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.
W Eiermann, S Paepke, +10 authors, Letrozole Neo-Adjuvant Breast Cancer Study Group.
Ann Oncol, 2002 Feb 02; 12(11). PMID: 11822750
Highly Cited.
Pharmacogenomics and Endocrine Therapy in Breast Cancer.
Daniel F Hayes, James M Rae.
J Clin Oncol, 2019 Dec 28; 38(6). PMID: 31880969
Interpreting quality-of-life data from the SOFT and TEXT trials.
Rowan T Chlebowski.
Lancet Oncol, 2015 Jun 21; 16(7). PMID: 26092819
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer.
Sara A Hurvitz, Miguel Martin, +16 authors, Dennis J Slamon.
Clin Cancer Res, 2019 Oct 17; 26(3). PMID: 31615937    Free PMC article.
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
Breast International Group (BIG) 1-98 Collaborative Group, Beat Thürlimann, +13 authors, Aron Goldhirsch.
N Engl J Med, 2005 Dec 31; 353(26). PMID: 16382061
Highly Cited.
A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR+ Early-Stage Breast Cancer with One to Three Positive Nodes.
Yi Zhang, Brock E Schroeder, +4 authors, Dennis C Sgroi.
Clin Cancer Res, 2017 Sep 25; 23(23). PMID: 28939745
Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis.
Hadar Goldvaser, Ibrahim AlGorashi, +4 authors, Eitan Amir.
Cancer Treat Rev, 2017 Sep 08; 60. PMID: 28881223
Systematic Review.
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Paul E Goss, James N Ingle, +15 authors, Joseph L Pater.
J Natl Cancer Inst, 2005 Sep 08; 97(17). PMID: 16145047
Highly Cited.
Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.
Matteo Lambertini, Halle C F Moore, +18 authors, Lucia Del Mastro.
J Clin Oncol, 2018 May 03; 36(19). PMID: 29718793    Free PMC article.
Highly Cited. Systematic Review.
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
William J Gradishar, Benjamin O Anderson, +28 authors, Rashmi Kumar.
J Natl Compr Canc Netw, 2016 Mar 10; 14(3). PMID: 26957618
Highly Cited.
Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus).
D Hind, L Wyld, C B Beverley, M W Reed.
Cochrane Database Syst Rev, 2006 Jan 27; (1). PMID: 16437480
Systematic Review.
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.
Jacquie H Chirgwin, Anita Giobbie-Hurder, +12 authors, Beat Thürlimann.
J Clin Oncol, 2016 May 25; 34(21). PMID: 27217455    Free PMC article.
Highly Cited.
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
A Howell, J Cuzick, +8 authors, ATAC Trialists' Group.
Lancet, 2005 Jan 11; 365(9453). PMID: 15639680
Highly Cited.
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
M M Regan, B A Walley, +15 authors, O Pagani.
Ann Oncol, 2017 Sep 16; 28(9). PMID: 28911092    Free PMC article.
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2019 Jun 04; 380(25). PMID: 31157962    Free PMC article.
Highly Cited.
Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials.
S P Corona, G Roviello, +17 authors, D Generali.
Breast, 2019 May 06; 46. PMID: 31051411
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Raimund Jakesz, Richard Greil, +12 authors, Austrian Breast and Colorectal Cancer Study Group.
J Natl Cancer Inst, 2007 Dec 13; 99(24). PMID: 18073378
Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools.
Julia Foldi, Tess O'Meara, +3 authors, Lajos Pusztai.
J Clin Oncol, 2019 Apr 04; 37(16). PMID: 30943126
Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis.
P Hadji, V Ziller, +4 authors, K Kostev.
Breast Cancer Res Treat, 2013 Jan 22; 138(1). PMID: 23334803
Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis.
Hadar Goldvaser, Tristan A Barnes, +4 authors, Eitan Amir.
J Natl Cancer Inst, 2017 Sep 20; 110(1). PMID: 28922781
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Alan S Coates, Aparna Keshaviah, +17 authors, Aron Goldhirsch.
J Clin Oncol, 2007 Jan 04; 25(5). PMID: 17200148
Highly Cited.
Aromatase expression in the human breast.
A Brodie, B Long, Q Lu.
Breast Cancer Res Treat, 1998 Oct 31; 49 Suppl 1. PMID: 9797022
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
Silvana Borges, Zeruesenay Desta, +11 authors, David A Flockhart.
Clin Pharmacol Ther, 2006 Jul 04; 80(1). PMID: 16815318
Highly Cited.
Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.
Dennis C Sgroi, Erin Carney, +16 authors, Paul E Goss.
J Natl Cancer Inst, 2013 Jul 03; 105(14). PMID: 23812955    Free PMC article.
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), C Davies, +11 authors, R Peto.
Lancet, 2011 Aug 02; 378(9793). PMID: 21802721    Free PMC article.
Highly Cited.
A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer.
Xiao-Jun Ma, Ranelle Salunga, +8 authors, Dennis Sgroi.
Clin Cancer Res, 2008 May 03; 14(9). PMID: 18451222
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Marco Colleoni, Weixiu Luo, +30 authors, SOLE Investigators.
Lancet Oncol, 2017 Nov 22; 19(1). PMID: 29158011
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Prudence A Francis, Olivia Pagani, +34 authors, SOFT and TEXT Investigators and the International Breast Cancer Study Group.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29863451    Free PMC article.
Highly Cited.
CDK4/6 inhibition in breast cancer: current practice and future directions.
Sonia Pernas, Sara M Tolaney, Eric P Winer, Shom Goel.
Ther Adv Med Oncol, 2018 Jul 25; 10. PMID: 30038670    Free PMC article.
Highly Cited. Review.
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Jack Cuzick, Ivana Sestak, +5 authors, ATAC/LATTE investigators.
Lancet Oncol, 2010 Nov 23; 11(12). PMID: 21087898
Highly Cited.
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.
N Lynn Henry, James M Rae, +11 authors, Consortium on Breast Cancer Pharmacogenomics Investigators.
Breast Cancer Res Treat, 2009 Jan 21; 117(3). PMID: 19153830    Free PMC article.
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Matthew P Goetz, Katrin Sangkuhl, +12 authors, Teri E Klein.
Clin Pharmacol Ther, 2018 Feb 01; 103(5). PMID: 29385237    Free PMC article.
Highly Cited.